Business
Study demonstrates Parsortix potential in melanoma
Study demonstrates Parsortix potential in melanoma.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 5502C Angle PLC 11 February 2020 \n\n \n\n\n\nFor immediate release\n\n\n11 February 2020\n\n\n\n \nANGLE plc (\"the Company\")\n \nNEW STUDY DEMONSTRATES POTENTIAL FOR PARSORTIX IN MELANOMA PROGNOSTICATION AND TREATMENT RESPONSE\n \n Parsortix out-performed alternative systems in head to head comparisons and was selected for molecular analysis in the study\n \nParsortix CTC score linked to progression-free and overall survival of patients \n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that a customer, the Edith Cowan University in Perth, Western Australia has published results of research into the use of ANGLE's Parsortix® system with melanoma patients. \n \nThe research shows that the Parsortix system can be used to investigate the heterogeneity of the cancer allowing full molecular analysis of the cancer. The researchers believe this opens the potential for liquid biopsy to be used for prognostication (assessing prognosis) and treatment response monitoring in melanoma.\n \nIn a pilot study of 28 melanoma patients, those with circulating tumour cells (CTCs) present in their blood, harvested by Parsortix, had significantly shorter overall survival with a hazard ratio of 7.8x meaning that patients with a positive Parsortix CTC score were 7.8x more likely to die during a 60 week follow-up period than those with a negative CTC score. In clinical use, the stratification of patients into high and low risk groups may allow improved treatment decisions, taking into account disease status. \n \nThe research also compared results from the Parsortix system with some competing systems using matched samples and determined that Parsortix yielded the highest recovery of CTCs and had lower white blood cell background. The Parsortix system also did not require pre-processing of the blood whereas the competing systems required a number of pre-processing steps to be undertaken manually to remove red blood cells prior to processing.\n \nThe research has been published as a peer-reviewed publication in the British Journal of Cancer and is available at https://angleplc.com/library/publications/. \n \nElin Gray, Associate Professor, Melanoma Research Group, Sc...